Columbia Laboratories (NASDAQ: CBRX) 71% LOWER; Announced its Phase III clinical trial of progesterone for the prevention of preterm birth ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE